Johnson & Johnson $JNJ Shares Purchased by Woodmont Investment Counsel LLC

Key Points

• Woodmont Investment Counsel LLC increased its stake in Johnson & Johnson by 4.4% during the 2nd quarter, owning 97,737 shares valued at approximately $14.93 million.
• Johnson & Johnson's quarterly earnings exceeded expectations with an EPS of $2.77, beating analyst estimates by $0.09 and showing a 5.8% revenue increase from the previous year.
• The company announced a quarterly dividend of $1.30 per share, translating to an annual yield of 2.8%, with a payout ratio of 55.61%.

Woodmont Investment Counsel LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97,737 shares of the company's stock after acquiring an additional 4,108 shares during the quarter. Johnson & Johnson comprises approximately 1.0% of Woodmont Investment Counsel LLC's investment portfolio, making the stock its 25th largest holding. Woodmont Investment Counsel LLC's holdings in Johnson & Johnson were worth $14,929,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Apexium Financial LP increased its holdings in Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after buying an additional 2,310 shares during the period. Avanza Fonder AB increased its holdings in Johnson & Johnson by 2.9% in the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after buying an additional 6,566 shares during the period. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its holdings in Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares during the period. Finally, Range Financial Group LLC increased its holdings in Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $188.95 on Wednesday. The company's fifty day moving average price is $177.04 and its 200 day moving average price is $163.18. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $189.92. The stock has a market capitalization of $455.06 billion, a P/E ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an "overweight" rating in a research note on Friday. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, HSBC raised their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $189.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.